Global Pemetrexed Drug Market Size By Type (100 mg lyophilized powder/vial, 500 mg lyophilized powder/vial), By Application (Pleural mesothelioma, Non-small cell lung cancer), By Region, And Segment F...

The Global Pemetrexed Drug Market was valued at USD 1.23 billion in 2023 and is projected to reach USD 2.07 billion by 2031, expanding at a CAGR of 6.8% during the forecast period (2023–2031). Pemetrexed, a chemotherapy agent primarily used to treat non-small cell lung cancer and mesothelioma, has gained notable traction due to the rising prevalence of cancer worldwide and the ongoing demand for effective anti-cancer drugs. Its inclusion in multiple first-line and second-line treatment regimens, combined with favorable reimbursement policies in developed markets, further accelerates its adoption.

Drivers

1. Rising Incidence of Lung Cancer Globally

The increasing number of non-small cell lung cancer (NSCLC) cases worldwide is a core driver for the pemetrexed drug market. Its proven efficacy and role in combination chemotherapy protocols enhance its medical demand.

2. Increased Preference for Targeted Chemotherapy

The shift from broad-spectrum chemotherapy to more targeted approaches, such as pemetrexed, that minimize side effects and improve patient outcomes, is stimulating market growth.

3. Supportive Regulatory Frameworks and Drug Approvals

The market benefits from a growing number of generic approvals and favorable policies supporting the use of pemetrexed, particularly in oncology-centric healthcare systems across North America and Europe.

Restraints

1. Patent Expirations and Generic Competition

Patent cliffs are opening the door for generic versions of pemetrexed, intensifying pricing pressures and reducing profit margins for original drug manufacturers.

2. Adverse Effects and Drug Resistance

Side effects such as anemia, nausea, and neutropenia can deter patient adherence. Additionally, the emergence of drug-resistant tumor variants poses a therapeutic challenge.

Opportunity

1. Expansion in Emerging Economies

Rapid urbanization, healthcare infrastructure improvements, and rising cancer prevalence in Asia-Pacific, Latin America, and parts of the Middle East are creating new avenues for market expansion.

2. Combination Therapies and Personalized Medicine

The evolving trend of combination chemotherapy—pairing pemetrexed with other agents or immunotherapies—is expected to unlock significant clinical and commercial potential. Moreover, advances in genomic profiling could personalize treatment regimens, boosting demand.

Market by System Type Insights

Based on drug formulation, the Injectable Pemetrexed segment held the dominant share in 2023. Intravenous delivery remains the standard due to its faster action and widespread clinical adoption in hospitals and oncology centers. However, research into alternative delivery methods—such as nanoparticle-based carriers—is expected to shape future developments.

Market by End-use Insights

In terms of end-use, Hospitals & Cancer Treatment Centers emerged as the largest revenue-generating segment in 2023, accounting for over 65% of global consumption. Their infrastructure, experienced oncology teams, and accessibility to branded drugs support the segment’s dominance. The Retail Pharmacies segment is also gaining traction with the rise in outpatient care and at-home chemotherapy management in high-income countries.

Market by Regional Insights

North America dominated the pemetrexed drug market in 2023 due to high cancer incidence rates, widespread access to advanced oncology treatments, and strong insurance coverage. Asia-Pacific, led by China and India, is anticipated to register the fastest CAGR through 2031. The growth is driven by rising healthcare investments, expanding pharmaceutical markets, and a growing patient pool.

Competitive Scenario

Prominent players in the global pemetrexed drug market include Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Hikma Pharmaceuticals, Fresenius Kabi, Mylan N.V., and Accord Healthcare. These companies are focused on biosimilar development, strategic collaborations, and regional expansion to strengthen market position.

Key Market Developments:

2023: Dr. Reddy's Laboratories launched a new generic version of pemetrexed in the U.S. under its oncology portfolio.

2024: Eli Lilly announced Phase II trials of a pemetrexed–immunotherapy combo for treatment-resistant NSCLC.

2025: Accord Healthcare expanded its manufacturing capacity in Europe for injectable oncology drugs, including pemetrexed.

Scope of Work – Global Pemetrexed Drug Market

FAQs

1) What is the current market size of the Global Pemetrexed Drug Market?

The market was valued at USD 1.23 billion in 2023.

2) What is the major growth driver of the Global Pemetrexed Drug Market?

The increasing prevalence of non-small cell lung cancer and adoption of targeted chemotherapy treatments.

3) Which is the largest region during the forecast period in the Global Pemetrexed Drug Market?

North America is expected to maintain its lead due to high cancer treatment expenditure and advanced healthcare infrastructure.

4) Which segment accounted for the largest market share in the Global Pemetrexed Drug Market?

The Injectable Pemetrexed segment led the market by formulation type in 2023.

5) Who are the key market players in the Global Pemetrexed Drug Market?

Key players include Eli Lilly and Company, Teva Pharmaceuticals, Dr. Reddy’s Laboratories, Hikma Pharmaceuticals, and Accord Healthcare.